Why the study?
Does heparin- and/or PGI2-immobilized PVC improve antithrombogenic activity in human blood?
Does heparin- and/or PGI2-immobilized PVC improve antithrombogenic activity in human blood?
Immobilizing heparin and/or PGI2 on PVC hydrogels provides significant antithrombogenic and antiplatelet activity, demonstrating potential for improving blood-contacting medical devices.
Should not change device selection; hypothesis-generating for antithrombogenic PVC coatings pending human studies.
Poly(vinyl chloride) (PVC) with heparin- and/or prostaglandin I 2 (PGI 2 )- immobilized on crosslinked polyacrylamide hydrogels were prepared by the ad dition of the dry hydrogels to a PVC tetrahydrofuran solution. Immobilized heparin was found to be continuously released from the PVC matrix at 37 ° C in a physiological saline. Antithrombogenic activity of PVCs with heparin and/or PGI 2 was evaluated by activated partial thromboplastin time (aPTT), whole blood clotting time, and inhibition of platelet aggregation. The heparin- immobilized PVC's exhibited excellent anticoagulant activity and the PGI 2 immobilized PVC's completely inhibit platelet aggregation of human blood after sitting for 46 h in a physiological saline.
No takes yet. Share an insight, caveat, or question.
Akashi et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: